Biotricity, Inc.

AI-generated fair value estimate for this company.

Method: 10-year unlevered FCF DCF: normalized FCF base of about $1.0M (derived from TTM operating income of $1.57M, the company's first sustained operating profit, haircut for growth capex on leased patient-monitoring devices); 12% FCF growth years 1-5, 6% years 6-10; 15% discount rate; 3% terminal growth. PV of years 1-10 FCF about $8.1M; PV of terminal value about $5.0M; enterprise value about $13.1M. Net debt of $26.46M (total debt $26.93M less cash $0.47M). Equity value = $13.1M less $26.46M = about -$13.4M, floored at $0 given limited liability of common equity.

Reasoning: Biotricity has turned operating-profitable so a DCF is appropriate, but its debt load alone exceeds the standalone operating value of the business against negative book equity, so intrinsic common-equity value is effectively zero, consistent with the stock's own minimal market capitalization.